Related Experiment Video
Updated: Jan 9, 2026
08:14
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
Published on: May 4, 2017
15.6K
Immune Modulation in Cancer: The Role of Tumor-Treating Fields (TTFields).
Menglan Liu1, Maria El Hage1, Jihui Zhao1
1Molecular Oncology and Immunotherapy, Clinic of General Surgery, University Medical Center Rostock, Rostock, Germany.
Current Protocols
|December 5, 2025
Summary
Tumor-treating fields (TTFields) disrupt cancer cell division and enhance immune responses. Combining TTFields with immunotherapy may improve cancer treatment outcomes by boosting efficacy.
Area of Science:
- Oncology
- Biophysics
- Immunology
Background:
- Tumor-treating fields (TTFields) use low-intensity electric fields to disrupt cancer cell division.
- TTFields exhibit direct cytotoxic effects and modulate the immune system.
- Immunotherapy has transformed cancer treatment, with immune-checkpoint inhibitors, cell therapies, and vaccines showing promise.
Purpose of the Study:
- To explore the synergistic potential of TTFields and immunotherapy.
- To investigate how TTFields enhance immunotherapeutic efficacy.
- To identify novel combinatorial strategies for improved cancer treatment.
Main Methods:
- Review of existing research on TTFields and immunotherapy.
- Analysis of TTFields' immune-modulatory mechanisms.
- Exploration of potential synergistic interactions.
Main Results:
- TTFields induce immunogenic cancer cell death, increasing immune cell infiltration.
- TTFields show potential to enhance the effectiveness of immunotherapies.
- Dual mechanisms of TTFields (cytotoxic and immune-modulatory) offer new treatment avenues.
Conclusions:
- TTFields possess immune-modulatory properties that complement immunotherapy.
- Combinatorial strategies involving TTFields and immunotherapy may improve patient outcomes.
- Further research into TTFields and immunotherapy synergy is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K